Outcome of Board Meeting held August 13, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board approved un-audited standalone and consolidated financial results for Q1FY26 (quarter ended June 30, 2025). Standalone revenue from operations fell sharply to Rs. 2,431.60 lakhs from Rs. 3,087.30 lakhs in the same quarter last year. The company swung to a standalone net loss of Rs. 166.27 lakhs (EPS of Rs. -3.37) versus a small profit of Rs. 20.83 lakhs last year. Consolidated loss was Rs. 167.38 lakhs. Major cost line of raw materials consumed rose to Rs. 1,975 lakhs even as revenue declined. The Board also appointed Ms. Sushmita Sonavane (ICSI member, LL.B.) as the new Company Secretary and Compliance Officer. Additionally, the company confirmed NIL deviation in the use of Rs. 6.57 crores raised through a preferential issue in November 2024 and March 2025.
The sharp revenue decline and swing to a quarterly loss is a negative signal for shareholders, pointing to weak demand or margin compression in the chemicals business. However, the appointment of a dedicated Company Secretary and clean utilisation of preferential issue funds provide some governance comfort.